Log In
Print
BCIQ
Print
Print this Print this
 

RSV vaccine

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionVaccine based on the company's PanAd3-RSV vaccine, a heterologous prime boost regimen with vectors encoding a string of respiratory syncytial virus (RSV) proteins bearing both B and T cell epitopes
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase I
Standard IndicationRespiratory syncytial virus (RSV)
Indication DetailsPrevent respiratory syncytial virus (RSV) infection
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today